Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 Oct 2016 - 12 Oct 2016
12 Nov 2016 - 16 Nov 2016

Drug Discovery

Image: A small library of abietane-type diterpenoids amides was prepared from the plant-based dehydroabietylamine (left (1)) as a starting material, and the compounds evaluated for activity against Leishmania donovani and Trypanosoma cruzi. One compound (right (10)), an amide built from dehydroabietylamine and acrylic acid, was found to be highly effective against both parasites (Photo courtesy of Pirttimaa M et al., 2016, Journal of Natural Products).

Newly Developed Drug Demonstrates Potent, Selective Activity Against Trypanosomatid Parasites

Using a plant-based compound, scientists have developed a semi-synthetic drug that, upon testing on infected mammalian cells in culture, showed highly effective activity against two parasites from the trypanosomatid family: Leishmania donovani, a cause of visceral leishmaniasis, and Trypanosoma cruzi, cause of Chagas disease.  More...
06 Apr 2016
Image: Structural model of the PAK1 protein (Photo courtesy of Wikimedia Commons).

Liposome Transport Protects Metabolic Activity of Prostate Cancer Drug

The efficacy of liposome transport to protect the physiological activity of a small-molecule anti-prostate cancer drug was demonstrated both in vitro and in a mouse xenograft model.  More...
30 Mar 2016
Image: The iNPG drug delivery process (Photo courtesy of Houston Methodist Research Institute).

Nanoparticle Drug Delivery Avoids Cancer Cells' Protein Pumps

A novel nanoparticle delivery system avoids excretion by cancer cells' protein pumps and transports the highly toxic anti-cancer drug doxorubicin directly into the nuclei of cancer cells without causing damage to normal tissues or cells.  More...
27 Mar 2016

Tumor Suppressor Gene Blocks Growth of Colon Cancer by Suppressing Key Tumor-Promoting Signaling Proteins

Cancer researchers have amassed a substantial body of evidence that points to the NLRX1 gene and its nlrx1 protein product as being powerful tumor suppressors that block the growth of colorectal cancer.  More...
22 Mar 2016

Novel Class of Drug Delivery Liposomes Fail to Trigger an Adverse Immune Response

A novel class of liposomes prepared from the artificial phospholipid Pad-PC-Pad releases drugs at the site of arterial blockage, and has been shown to avoid activation of deleterious immune responses.  More...
22 Mar 2016
Image: Mode of action of the dual cyclin kinase inhibitor ON123300 (Photo courtesy of Onconova Therapeutics).

Dual Cyclin-Dependent Kinase Inhibitor Effective Against Multiple Myeloma in Preclinical Studies

Results obtained during preclinical studies support the continued development of a dual cyclin-dependent kinase inhibitor for the treatment of multiple myeloma.  More...
16 Mar 2016

Experimental Drug Blocks Leukemia Growth in Mouse Model System

An experimental drug that blocks the activity of a specific histone demethylase enzyme was found to cure the TAL-1 form of acute T-cell lymphoblastic leukemia in a mouse model system.  More...
14 Mar 2016


The Drug Discovery channel in BioResearch informs about the biotechnology of drug discovery and design from traditional to translational pharma within the five-year horizon.
Copyright © 2000-2016 Globetech Media. All rights reserved.